A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, double-dummy, positive-controlled, phase 3 study to assess the
safety and efficacy of TLL-018 in active rheumatoid arthritis subjects who had an inadequate
response or intolerance to Biologic DMARDs.